



Hans J. Crosby
Associate
Phone (202) 775-5772
Fax 202/857-8395
crosbyhj@arentfox.com
www.arentfox.com

FACSIMILE TRANSMITTAL COVER SHEET

Date: March 6, 2001, 3:36 PM

No. of Pages: 5
(Including Cover Sheet)

PLEASE DELIVER TO:

Name:	Fax Number:	Verify Number:
Examiner F. Lu	703-308-8724	703-305-1270
Art Unit: 1655		
U.S. Patent & Trademark Office		

Attorney Number: 1733 **Client/Matter Number:** 100564-09051

Hard Copy Sent: No

Comments:

10. MAR-6 PM 3:36

THIS FACSIMILE CONTAINS PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE ADDRESSEE(S) NAMED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT OF THIS FACSIMILE, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR COPYING OF THIS FACSIMILE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND RETURN THE ORIGINAL FACSIMILE TO US AT THE ADDRESS BELOW VIA THE POSTAL SERVICE. THANK YOU.

Please Call As Soon As Possible If Transmission Is Not Complete:
202/857-6119

Arent Fox Kintner Plotkin & Kahn, PLLC
1050 Connecticut Ave., N.W., Washington, D.C. 20036-5339

official
Please enter
3/1/2001
file in

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/c
B. Webb
3/7/01

In re the application of:

ULLRICH et al.

Group Art Unit: 1655

Serial Number: 09/461,090

Examiner: F. Lu

Filed: December 14, 1999

For: EGF RECEPTOR TRANSACTIVATION BY G-PROTEIN-COUPLED
RECEPTORS REQUIRES METALLOPROTEINASE CLEAVAGE OF
proHB-EGFSUPPLEMENTAL AMENDMENTCommissioner for Patents
Washington, D.C. 20231

March 6, 2001

Sir:

This paper is filed in response to the telephone discussions between the Examiner and Counsel on February 8, 2001 and March 6, 2001, in connection with the above-identified patent application. Applicants respectfully request entry of the following amendments without prejudice.

In the claims:

Please amend claims 1 and 20 as follows. Attached is a marked up copy of the claims which indicates the changes to the claims.

SwDDI
CH

Claim 1 (Amended).

A method for modulating growth-factor activation comprising contacting a cell which contains a growth-factor receptor capable of being activated with a modulator of G-protein mediated signal transduction, or an organism comprising such a cell, so